Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ERIC W CHAK

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1225271331
CMS profile
1395900
Location
DAVIS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$19.44

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $19.44 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $19.44 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ERIC W CHAK

NPI 1225271331 · CMS profile ID 1395900

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

DAVIS, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1225271331?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ERIC W CHAK, NPI 1225271331, CMS profile ID 1395900. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1225271331?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ERIC W CHAK, NPI 1225271331, CMS profile ID 1395900. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1225271331?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ERIC W CHAK, NPI 1225271331, CMS profile ID 1395900, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1225271331?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $19.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $19.4403/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747958529 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,239.98 2
PY2020 $19.44 1
PY2024 $19.75 1
PY2025 $351.63 15

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $97,886.19 59
PY2024 Principal investigator $119,281.64 31
PY2023 Principal investigator $187,958.54 29
PY2022 Principal investigator $229,906.35 24
PY2021 Principal investigator $76,828.17 6
PY2020 Principal investigator $68,800.00 3
PY2019 Principal investigator $31,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GlaxoSmithKline, LLC. $7,827.42 09/18/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIF
A PROSPECTIVE, MULTI CENTRE STUDY (B-SURE) TO EVALUATE LONG TERM DURAB No dispute reported 06/30/2026 1192167390
Principal investigator 1 GlaxoSmithKline, LLC. $1,370.36 09/05/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192168784
Principal investigator 1 GlaxoSmithKline, LLC. $415.80 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192111734
Principal investigator 1 GlaxoSmithKline, LLC. $3,432.00 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192111740
Principal investigator 1 GlaxoSmithKline, LLC. $68.64 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192111753
Principal investigator 1 GlaxoSmithKline, LLC. $137.28 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192111762
Principal investigator 1 GlaxoSmithKline, LLC. $415.80 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192111769
Principal investigator 1 GlaxoSmithKline, LLC. $68.64 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192111774
Principal investigator 1 GlaxoSmithKline, LLC. $1,663.20 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192116286
Principal investigator 1 GlaxoSmithKline, LLC. $5,462.16 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192116292
Principal investigator 1 GlaxoSmithKline, LLC. $2,079.00 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192116307
Principal investigator 1 GlaxoSmithKline, LLC. $1,980.00 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192116329
Principal investigator 1 GlaxoSmithKline, LLC. $396.00 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192119610
Principal investigator 1 GlaxoSmithKline, LLC. $831.60 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192119617
Principal investigator 1 GlaxoSmithKline, LLC. $415.80 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192119630
Principal investigator 1 GlaxoSmithKline, LLC. $1,980.00 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192121329
Principal investigator 1 GlaxoSmithKline, LLC. $198.00 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192121335
Principal investigator 1 GlaxoSmithKline, LLC. $396.00 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192121343
Principal investigator 1 GlaxoSmithKline, LLC. $274.56 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192167414
Principal investigator 1 GlaxoSmithKline, LLC. $68.64 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192168757
Principal investigator 1 GlaxoSmithKline, LLC. $295.68 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192168761
Principal investigator 1 GlaxoSmithKline, LLC. $343.20 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192168775
Principal investigator 1 GlaxoSmithKline, LLC. $68.64 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192168780
Principal investigator 1 GlaxoSmithKline, LLC. $198.00 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171075
Principal investigator 1 GlaxoSmithKline, LLC. $415.80 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171780
Principal investigator 1 GlaxoSmithKline, LLC. $137.28 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171784
Principal investigator 1 GlaxoSmithKline, LLC. $831.60 08/25/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171788
Principal investigator 1 GlaxoSmithKline, LLC. $1,600.00 07/24/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIF
A PROSPECTIVE, MULTI CENTRE STUDY (B-SURE) TO EVALUATE LONG TERM DURAB No dispute reported 06/30/2026 1192167398
Principal investigator 1 GlaxoSmithKline, LLC. $6,513.00 07/18/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIF
A PROSPECTIVE, MULTI CENTRE STUDY (B-SURE) TO EVALUATE LONG TERM DURAB No dispute reported 06/30/2026 1192167394
Principal investigator 1 GlaxoSmithKline, LLC. $1,631.72 06/11/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192168789
Principal investigator 1 GlaxoSmithKline, LLC. $2,907.04 05/09/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171092
Principal investigator 1 GlaxoSmithKline, LLC. $1,453.52 04/09/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171800
Principal investigator 1 GlaxoSmithKline, LLC. $137.28 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192111747
Principal investigator 1 GlaxoSmithKline, LLC. $831.60 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192111760
Principal investigator 1 GlaxoSmithKline, LLC. $1,045.44 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192116299
Principal investigator 1 GlaxoSmithKline, LLC. $68.64 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192116313
Principal investigator 1 GlaxoSmithKline, LLC. $1,980.00 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192116317
Principal investigator 1 GlaxoSmithKline, LLC. $1,663.20 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192116322
Principal investigator 1 GlaxoSmithKline, LLC. $1,600.00 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192119594
Principal investigator 1 GlaxoSmithKline, LLC. $137.28 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192119599
Principal investigator 1 GlaxoSmithKline, LLC. $295.68 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192119604
Principal investigator 1 GlaxoSmithKline, LLC. $415.80 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192119623
Principal investigator 1 GlaxoSmithKline, LLC. $411.84 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192119638
Principal investigator 1 GlaxoSmithKline, LLC. $831.60 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192121321
Principal investigator 1 GlaxoSmithKline, LLC. $205.92 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192167405
Principal investigator 1 GlaxoSmithKline, LLC. $3,484.80 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192167409
Principal investigator 1 GlaxoSmithKline, LLC. $1,980.00 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192168766
Principal investigator 1 GlaxoSmithKline, LLC. $274.56 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171063
Principal investigator 1 GlaxoSmithKline, LLC. $1,716.00 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171071
Principal investigator 1 GlaxoSmithKline, LLC. $2,079.00 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171079
Principal investigator 1 GlaxoSmithKline, LLC. $13,004.64 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171082
Principal investigator 1 GlaxoSmithKline, LLC. $2,574.00 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171086
Principal investigator 1 GlaxoSmithKline, LLC. $5,462.16 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171793
Principal investigator 1 GlaxoSmithKline, LLC. $1,663.20 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171796
Principal investigator 1 GlaxoSmithKline, LLC. $2,494.80 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171805
Principal investigator 1 GlaxoSmithKline, LLC. $343.20 04/01/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171809
Principal investigator 1 GlaxoSmithKline, LLC. $1,536.68 03/21/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192168770
Principal investigator 1 GlaxoSmithKline, LLC. $1,453.52 02/06/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192167401
Principal investigator 1 GlaxoSmithKline, LLC. $4,318.97 01/08/2025 Non-covered Recipient Entity
REGENTS OF THE UNIVERSITY OF CALIFORNIA
PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF No dispute reported 06/30/2026 1192171067